Grace Therapeutics Inc logo

Grace Therapeutics Inc

NEW
NAS:GRCE (USA)   Ordinary Shares
$ 2.56 +0.030 (+1.19%) 12:08 AM EST
At Loss
P/B:
0.50
Market Cap:
$ 35.12M
Enterprise V:
$ 11.70M
Volume:
37.79K
Avg Vol (2M):
81.83K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
37.79K
At Loss
Avg Vol (2M):
81.83K

Business Description

Grace Therapeutics Inc logo
Grace Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : CA00430K4028

Share Class Description:

GRCE: Ordinary Shares
Description
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.85
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.06
Quick Ratio 6.06
Cash Ratio 5.61

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -29.4

Financials (Next Earnings Date:2025-06-20 Est.)

GRCE's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:GRCE

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Grace Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.54
Beta 0.84
3-Year Sharpe Ratio -0.2
3-Year Sortino Ratio -0.31
Volatility % 34.49
14-Day RSI 43.15
14-Day ATR ($) 0.216704
20-Day SMA ($) 2.5742
12-1 Month Momentum % -16.72
52-Week Range ($) 2.07 - 4.965
Shares Outstanding (Mil) 13.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Grace Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Grace Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Grace Therapeutics Inc Frequently Asked Questions

What is Grace Therapeutics Inc(GRCE)'s stock price today?
The current price of GRCE is $2.56. The 52 week high of GRCE is $4.97 and 52 week low is $2.07.
When is next earnings date of Grace Therapeutics Inc(GRCE)?
The next earnings date of Grace Therapeutics Inc(GRCE) is 2025-06-20 Est..
Does Grace Therapeutics Inc(GRCE) pay dividends? If so, how much?
Grace Therapeutics Inc(GRCE) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1